Read More

Disney’s Proxy Battle Enters Critical Phase, Gains Ground Against Trian as Major Investors Back CEO Iger

Amid a proxy battle with Trian Partners, Walt Disney gains traction as major investors like BlackRock and T. Rowe Price back Disney. This support boosts CEO Bob Iger amid efforts to resist Trian's board representation push. The outcome remains uncertain as shareholders cast votes ahead of the annual meeting.

BLK

Read More

EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug

PainReform hits a 50% enrollment target in the Phase 3 trial for PRF-110 in bunionectomy. No serious adverse events were reported. Over 200 patients enrolled across 8 U.S. sites. CEO Ilan Hadar is optimistic about PRF-110's potential to revolutionize postoperative pain management.

PRFX